Hormone replacement therapy has been studied in 1,019 papers since 1996: 30 trials and 364 observational studies in people, 5 in animals, 604 reviews; 509 in the past year. The newest story, Nov 17, 2026: “Longer reproductive span linked to lower osteoporosis risk”.
Independent labs found the same change in people. 212 independent labs in 54 countries.
“Randomization to oral MHT did not increase CHD risk in participants with a history of treated hyperlipidemia or in untreated participants with favorable lipid profiles”
Humans: replicated by independent labs. Mice: a single group. Cells and worms or flies: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
16,608 peopleWomen50-79 yearsOlder adults; Midlife adults; Postmenopausal women; history of treated hyperlipidemia or untreated with favorable lipid profiles
60 peopleWomen40-85 yearsMidlife adults; Older adults; Postmenopausal women; both partnership groups
Frontiers in global women's health, Jun 2, 2026
What did studies of hormone replacement therapy find?
269
Studies of hormone replacement therapy measured 269 outcomes; the most studied are menopausal symptoms (27 studies), quality of life (13) and mortality (11).
Hormone replacement therapy improves menopausal symptoms in humans (perimenopause or postmenopause) (3 of 5 women).
“Three women reported relief of menopausal symptoms (eg, sleep disturbance, vasomotor symptoms, and joint pain), which was perceived as beneficial to mental stability.”
Human trialperimenopause or postmenopause3 monthsfemalesn = 5
Hormone replacement therapy decreases menopausal symptoms in humans (menopausal transition) (Greene scale score from 16.01±4.12 to 4.02±3.12 points).
“the significantly decreased mean final Green's scale score was observed: from 17.12±3.28 to 6.12±4.34 points in group 1 and from 16.01±4.12 to 4.02±3.12 points in group 2.”
Human trialmenopausal transition1 monthfemalesn = 16
Hormone replacement therapy is linked with lower menopausal symptoms in humans (natural menopause; tibolone or isoflavones).
“the women who participated and received HRT consisting of either tibolone or phytoestrogen isoflavones showed a significant and immediate reduction in symptoms”
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·
Hormone replacement therapy improves quality of life in humans (menopause).
“Significant improvements were also observed in vasomotor symptoms, sleep quality, psychological well-being, and sexual function, promoting better quality of life.”
Hormone replacement therapy improves quality of life in humans.
“Hormone replacement therapy has the potential to improve quality of life by treating bothersome symptoms and delaying the physical changes brought on by loss of estrogen.”
Hormone replacement therapy is linked with lower mortality in humans after chemoradiotherapy for cervical cancer (HR 0.81 (95% CI 0.63-0.91)).
“The use of hormone therapy was also associated with significantly improved overall survival (hormone therapy, 0.81; 95% confidence interval, 0.63-0.91).”
Humansafter chemoradiotherapy for cervical cancerfemales
Hormone replacement therapy was not clearly linked with mortality in humans (death from breast cancer; current vs. never HRT use) (HR 0.85 (95% CI, 0.40, 1.78)).
“did not associate with risk of death from BC (HR current vs. never, 0.85; 95% CI, 0.40, 1.78)”
Humansdeath from breast cancer; current vs. never HRT usefemales
Hormone replacement therapy decreases mortality in humans (timely initiated).
“Timely initiated MHT (within the first 10 years after menopause) is also associated with a decrease in all-cause mortality, cardiovascular complications, and neurodegenerative diseases.”
“However, a significant reduction in all-cause mortality was observed among post-menopausal HF patients who received HRT (RR: 0.65, 95% CI: 0.49-0.87, p = 0.003).”
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Menopausal Hormone Therapy (MHT) is established as the most effective treatment, particularly when initiated within the “timing window” (aged <60 years or within 10 years of onset)”
Hormone replacement therapy decreases vasomotor symptoms in humans (selected women with premature menopause without contraindications).
“Menopausal hormone therapy (MHT) should be considered for premature menopause management in selected women without contraindications, improving both vasomotor symptoms and sleep quality.”
Reviewselected women with premature menopause without contraindicationsfemales
Hormone replacement therapy decreases vasomotor symptoms in humans.
“Current evidence from clinical studies and meta-analyses unequivocally demonstrates that hormone replacement therapy is the most efficacious treatment for vasomotor and urogenital symptoms”
International Journal of Innovative Technologies in Social Science·
Vasomotor symptoms
↓downin humans9
9 studies
Hormone replacement therapy decreases vasomotor symptoms in humans (eligible women after risk-reducing salpingo-oophorectomy).
“For eligible women, menopausal hormone therapy (MHT) is the most effective treatment for vasomotor symptoms and prevents estrogen‐deficiency bone loss.”
Revieweligible women after risk-reducing salpingo-oophorectomyfemales
Hormone replacement therapy decreases vasomotor symptoms in humans (menopause).
“Menopausal hormonal therapy (MHT) is supported by level 1 evidence and can address many of the negative impacts associated with menopause, including VMS.”
Hormone replacement therapy was not clearly linked with cognitive function in humans (postmenopausal women followed ~10 years post-trial).
“Tests assessing the effects of mHT allocation on cognitive slopes during the KEEPS and across all years of follow-up including the KEEPS Continuation visit were all statistically nonsignificant.”
Humanspostmenopausal women followed ~10 years post-trial10 yearsfemalesn = 275
Hormone replacement therapy showed no clear effect on cognitive function in humans (young menopausal women).
“Menopausal hormone therapy in young menopausal women was not shown to have beneficial effects on cardiovascular disease, cancer, depression, or cognition”
Hormone replacement therapy improves cognitive function in humans (initiated early in menopausal transition for menopausal symptoms).
“MHT initiated early in the menopausal transition for menopausal symptoms has the strongest evidence for sustaining cognitive function and reducing Alzheimer's risk.”
Reviewinitiated early in menopausal transition for menopausal symptomsfemales
Liver international : official journal of the International Association for the Study of the Liver·
Hormone replacement therapy was not clearly linked with breast cancer in humans (breast cancer familial risk score of 0.4 or higher) (HR 1.01 (95% CI 0.82 to 1.25)).
“1.01 (95% CI = 0.82 to 1.25) for a breast cancer familial risk score of 0.4 or higher”
Humansbreast cancer familial risk score of 0.4 or higherfemales
Hormone replacement therapy showed no clear effect on breast cancer (BRCA mutation carriers after risk-reducing salpingo-oophorectomy; short course).
“a short course of hormone replacement therapy does not increase breast cancer risk in BRCA mutation carriers after risk-reducing salpingo-oophorectomy”
ReviewBRCA mutation carriers after risk-reducing salpingo-oophorectomy; short courseshort coursefemales
Annals of oncology : official journal of the European Society for Medical Oncology·
Hormone replacement therapy showed no clear effect on breast cancer in humans (non-randomized prospective observational studies in breast cancer survivors).
“no increased risk of recurrence was reported in the observational studies”
Reviewnon-randomized prospective observational studies in breast cancer survivorsbreastfemales
Hormone replacement therapy showed no clear effect on breast cancer in humans (early menopause after preventive surgery, including BRCA1 and BRCA2 carriers).
“HRT for women in early menopause does not increase breast cancer risk, including in those who are BRCA1 and BRCA2 carriers and have preventative surgery.”
Reviewearly menopause after preventive surgery, including BRCA1 and BRCA2 carriersfemales
International Journal of Research in Medical Sciences·
Hormone replacement therapy increases bone mineral density in humans (compared with exercise therapy alone) (greater improvements than exercise therapy alone; no numbers given).
“there were greater improvements in BMD than exercise therapy alone”
Reviewcompared with exercise therapy alonebonefemales
Hormone replacement therapy protects against menopausal symptoms in RRSO group.
“When restricted to the RRSO group who took hormone replacement therapy, there was no significant worsening of total sexual function scores or menopausal symptoms compared with baseline.”
Hormone replacement therapy decreases menopausal symptoms in humans.
“While menopausal hormone therapy (MHT) is the most effective treatment, contraindications such as estrogen-sensitive cancers and thromboembolic conditions limit its use for many women”
Hormone replacement therapy showed no clear effect on coronary artery disease in humans (history of treated hyperlipidemia or untreated with favorable lipid profiles).
“Randomization to oral MHT did not increase CHD risk in participants with a history of treated hyperlipidemia or in untreated participants with favorable lipid profiles”
Human trialhistory of treated hyperlipidemia or untreated with favorable lipid profilesoralfemales
Hormone replacement therapy protects against coronary artery disease in humans (started early after menopause (timing hypothesis)).
“Recent evidence supports the cardioprotective effects of HRT when started early after menopause, ideally within ten years or before the age of sixty, in line with the "timing hypothesis".”
Reviewstarted early after menopause (timing hypothesis)
Hormone replacement therapy decreases IL-1β in humans (oral MHT) (from 0.46 (0.26; 0.66) pg/mL to 0.26 (0.06; 0.56) pg/mL).
“In addition, a significant reduction in IL-1β levels from 0.46 (0.26; 0.66) pg/mL to 0.26 (0.06; 0.56) pg/mL (p = 0.039) was observed after 12 weeks of oral MHT ( a).”
Hormone replacement therapy decreases MCP-1 in humans (oral and transdermal MHT) (from 10.23 (6.90; 13.96) pg/mL to 8.71 (5.39; 11.71) pg/mL and from 11.32 (9.53; 12.81) pg/mL to 8.72 (6.21; 12.29) pg/mL).
“According to the data presented, after 12 weeks of using both oral and transdermal MHT in women, there was a significant decrease in the level of MCP-1 from 10.23 (6.90; 13.96) pg/mL to 8.71 (5.39; 11.71) pg/mL (p = 0.022) and from 11.32 (9.53; 12.81) pg/mL to 8.72 (6.21; 12.29) pg/mL (p = 0.026), respectively”
Human trialoral and transdermal MHT12 weeksfemalesn = 50
Hormone replacement therapy decreases MCP-1 in menopausal patients.
“different routes of MHT administration led to significant changes in monocyte phenotype and a decrease in monocyte chemoattractant protein-1 (MCP-1) level in menopausal patients”
Human trialin menopausal patientsoral or transdermalfemales
Hormone replacement therapy decreases menopause Rating Scale total score in humans (Moderate-to-severe menopausal syndrome; compared with integrative care) (Adjusted mean difference −6.4; 95% CI −7.8 to −5.0).
“HRT produced more rapid symptomatic improvement at 6 months (adjusted mean difference −6.4; 95% confidence interval −7.8 to −5.0; p < 0.001).”
Human trialModerate-to-severe menopausal syndrome; compared with integrative care6 monthsfemalesn = 500
Hormone replacement therapy increases ovarian volume in humans.
“AFC, ovarian volume, and E2 all increased significantly in both groups compared with baseline (P < 0.05).”
Human trialDiminished ovarian reserve; combined with acupoint catgut embedding or sham acupoint embedding; compared with baselineovary3 treatment cycles
Hormone replacement therapy is linked with a lower risk of breast cancer in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.786, 95% CI 0.743-0.831).
“lower hazards of breast cancer (events: 1281 vs 1504; crude incidence: 1.53% vs 1.80%; HR: 0.786, 95% CI: 0.743-0.831)”
Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670
The Journal of clinical endocrinology and metabolism·
Hormone replacement therapy is associated with breast cancer in humans (adjusted multivariable logistic regression models) (ORa 6.052-7.146; p = 0.010-0.031).
“The use of hormone replacement therapy (HRT) was significantly associated with breast cancer history (ORa 6.052-7.146, p = 0.010-0.031)”
Hormone replacement therapy is linked with a lower risk of breast cancer in BRCA1 or BRCA2 carriers, exposed versus unexposed matched women (12.9% versus 18.9% incident cases).
“there were 87 (12.9%) incident breast cancer cases in the 676 exposed women and 128 (18.9%) cases in the 676 unexposed women (P = .002)”
Humansin BRCA1 or BRCA2 carriers, exposed versus unexposed matched womenfemalesn = 676
Hormone replacement therapy is linked with a higher risk of breast cancer in humans (Current users compared with never users) (HR 1.44 (95% CI 1.36–1.52)).
“MHT use was associated with increased risk of overall, luminal A-like, and luminal B-like breast cancer”
HumansCurrent users compared with never usersestrogen-progestin therapyfemales
Hormone replacement therapy is linked with a higher risk of breast cancer in humans (AOR 5.02, 95 % CI: 1.93-13.06).
“Women who used hormone replacement therapy (HRT) were significantly associated with higher odds (5 folds) of having breast ca versus those who did not use them (AOR 5.02, 95 % CI: 1.93-13.06, p = 0.001).”
Hormone replacement therapy is linked with a lower risk of breast cancer in humans (versus control patients) (0.26% vs 1.38%, p<=0.004).
“the breast cancer risk in bisphosphonates ever use group (12/2326, 0.52%), statins ever use group (99/15287, 0.65%), hormone users for menopausal symptoms (20/7631, 0.26%) are significantly lower than control patients”
Hormone replacement therapy is linked with a lower risk of cardiovascular disease in humans (perimenopausal and recently postmenopausal women with vasomotor symptoms) (aHR 0.78, 95% CI 0.62-0.98).
“adjusted hazard ratio (aHR) of CVD events for MHT initiation vs noninitiation was 0.78 (95% CI, 0.62-0.98)”
Humansperimenopausal and recently postmenopausal women with vasomotor symptoms20-year follow-upfemalesn = 2,737
Hormone replacement therapy is linked with a lower risk of cardiovascular disease in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.699, 95% CI 0.688-0.709).
“and CVD (events: 3960 vs 4413; crude incidence: 4.74% vs 5.29%; HR: 0.699, 95% CI: 0.688-0.709)”
Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670
Hormone replacement therapy is associated with cardiovascular disease in humans (women veterans; compared with no menopausal hormone therapy) (HR 1.74, 95% CI 1.63–1.85).
“HT was independently associated with a greater risk of CVD (HR = 1.74, 95% CI: 1.63-1.85)”
Humanswomen veterans; compared with no menopausal hormone therapyoral or transdermal estrogen-containing product or combined estrogen-progestinfemales
European heart journal. Quality of care & clinical outcomes·
Hormone replacement therapy is associated with cardiovascular disease in humans (Prior pre-eclampsia; compared with MHT non-users) (HR 0.85, 95% CI 0.78–0.91).
“The use of MHT in prior pre-eclamptic women was associated with significant risk reductions for any CVD (HR 0.85, 95 % CI 0.78-0.91)”
HumansPrior pre-eclampsia; compared with MHT non-usersMean follow-up 13.3 yearsfemales
Hormone replacement therapy lowers the risk of bone fracture.
“hormone replacement therapy, vitamin D supplements, and lifestyle changes, are critical for maintaining good bone health and lowering the risk of fracture”
Journal of ISAKOS : joint disorders & orthopaedic sports medicine·
Hormone replacement therapy lowers the risk of bone fracture in humans (particularly the combination of estradiol and dydrogesterone).
“Clinical studies demonstrate a significant increase in bone mineral density and a reduction in the risk of fractures with the use of MHT, particularly the combination of estradiol and dydrogesterone.”
Reviewparticularly the combination of estradiol and dydrogesterone
Hormone replacement therapy raises the risk of venous thromboembolism in humans (as reported by the Women's Health Initiative randomised placebo-controlled trial).
“They suggested that hormone replacement therapy (HRT) use increased the risk of cardiovascular disease and venous thromboembolism including pulmonary embolism and deep vein thrombosis”
Reviewas reported by the Women's Health Initiative randomised placebo-controlled trialfemales
Hormone replacement therapy is associated with Alzheimer's disease in humans (Initiated within 10 years of menopause) (1.4% vs 1.7%; RR 0.81, 95% CI 0.70-0.92).
“HRT was associated with lower risks of stroke/TIA (6.4% vs 7.5%; RR 0.86, 95% CI 0.81-0.91; p<0.001) and AD (1.4% vs 1.7%; RR 0.81, 95% CI 0.70-0.92; p=0.002).”
HumansInitiated within 10 years of menopausefemales
Hormone replacement therapy is linked with a lower risk of Alzheimer's disease in postmenopausal women with chronic kidney disease; adjusted Cox regression (HR 0.80; 95% CI 0.77-0.82).
“Alzheimer's disease: HR 0.80; 95% CI 0.77-0.82; p < 0.001”
Humansin postmenopausal women with chronic kidney disease; adjusted Cox regressionfemalesn = 755,426
Hormone replacement therapy is associated with Alzheimer's disease in women.
“Exposure to HRT may modify the development of AD; however, data are weak and the influence of timing, duration, type of HRT, and ethnic, socioeconomic, educational and genomic factors such as APOE genotype, requires further clarification.”
Hormone replacement therapy is associated with Alzheimer's disease in humans (women with a uterus; compared with placebo or no menopausal hormone therapy) (HR 1.14, 95% CI 1.02–1.29).
“Initiating MHT in women with a uterus around the age of menopause increased the risk of Alzheimer’s disease slightly, by over 10%”
Reviewwomen with a uterus; compared with placebo or no menopausal hormone therapysystemicfemalesn = 134,865
Hormone replacement therapy lowers the risk of Alzheimer's disease in humans (for menopause-related symptoms).
“Medical informatic analyses of real‐world menopausal hormone therapy (MHT) for menopause‐related symptoms indicates a significant reduction in risk of Alzheimer's disease.”
Hormone replacement therapy lowers the risk of Alzheimer's disease in humans (early and premature menopause).
“Menopausal hormone therapy from menopause to the age of 60 years may provide a "window of opportunity" to reduce the risk of mild cognitive impairment (MCI) and AD in later life.”
Hormone replacement therapy is linked with a higher risk of dementia in humans (20.04 vs 15.79 per 1,000; adjusted HR 1.35 (95% CI 1.13-2.62)).
“the cumulative incidence of dementia for the HRT cohort (20.04 per 1,000) was significantly higher than the corresponding cumulative incidence for the comparison cohort (15.79 per 1,000)”
Hormone replacement therapy lowers the risk of dementia in humans (initiation within five years of menopause) (pooled aRR 0.66, 95% CI 0.53 to 0.83, p = 0.0003).
“Initiation within five years of menopause was associated with a clinically meaningful reduction in dementia risk (pooled aRR 0.66, 95% CI 0.53 to 0.83”
International Journal of Innovative Technologies in Social Science·
Hormone replacement therapy is associated with dementia in humans.
“The available evidence indicates that estrogen plays a significant role in influencing dementia risk, with studies demonstrating both beneficial and detrimental effects of HRT.”
Hormone replacement therapy raises the risk of dementia in humans (RR 1.38, 95% CI 1.16–1.64).
“Randomized controlled trials conducted in postmenopausal women ages 65 and older show an increased risk of dementia with HT use compared with placebo”
ReviewPostmenopausal women; pooled randomized controlled trials comparing hormone therapy with placebofemales
Hormone replacement therapy raises the risk of dementia in humans (initiated in predominantly comorbid postmenopausal women) (approximately 2-fold).
“WHIMS) reported an approximately 2-fold increased risk of dementia/Alzheimer's disease if MHT comprising conjugated equine estrogens and medroxyprogesterone acetate was initiated in predominantly comorbid postmenopausal women above age 65.”
Reviewinitiated in predominantly comorbid postmenopausal womenconjugated equine estrogens and medroxyprogesterone acetatefemales
Hormone replacement therapy is associated with mortality in humans (women veterans; compared with no menopausal hormone therapy) (HR 1.25, 95% CI 1.13–1.39).
“the HT cohort had significantly higher rates of CVD compared to the non-HT cohort (22.4% vs. 11.7%, P < 0.001), and all-cause mortality”
Humanswomen veterans; compared with no menopausal hormone therapyoral or transdermal estrogen-containing product or combined estrogen-progestinfemales
European heart journal. Quality of care & clinical outcomes·
Hormone replacement therapy is linked with a lower risk of mortality in humans (combined HRT users compared with non-users, matched on age and general practice) (HR 0.91 (95% CI 0.88-0.94)).
“The adjusted hazard ratio (HR) of overall all-cause mortality in combined HRT users was 0.91 (95% CI 0.88-0.94)”
Humanscombined HRT users compared with non-users, matched on age and general practicecombinedfemales
Hormone replacement therapy is associated with stroke in humans (varies depending on formulation, route, age, and health).
“menopausal hormone therapy, a leading approach to managing menopausal symptoms, has implications for stroke risk, which varies depending on the menopausal hormone therapy formulation, route of delivery, and the age”
Reviewvaries depending on formulation, route, age, and health
Hormone replacement therapy raises the risk of stroke in humans (Perimenopausal or postmenopausal women; meta-analyses of randomized controlled trials) (RR 1.17, 95% CI 1.05 to 1.29).
“but harmful for stroke (17 trials, 37,272 women, RR 1.17, 95% CI 1.05 to 1.29, p = 0.027)”
ReviewPerimenopausal or postmenopausal women; meta-analyses of randomized controlled trialsfemalesn = 37,272
Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans (menopause at age ≤60 years; propensity-matched new users vs non-users) (HR 0.595, 95% CI 0.575-0.615).
“lower hazards of T2DM (events: 3517 vs 4580; crude incidence: 4.20% vs 5.47%; HR: 0.595, 95% CI: 0.575-0.615)”
Humansmenopause at age ≤60 years; propensity-matched new users vs non-usersestrogen and/or progestogenfemalesn = 83,670
Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans after chemoradiotherapy for cervical cancer (5.3% vs 9.8%; HR 0.59 (95% CI 0.32-0.81)).
“Compared with nonhormone therapy users, hormone therapy use was associated with a significantly lower risk of type 2 diabetes mellitus (5.3% vs 9.8%; hazard ratios, 0.59; 95% confidence interval, 0.32-0.81)”
Humansafter chemoradiotherapy for cervical cancerfemales
Hormone replacement therapy is linked with a lower risk of type 2 diabetes in humans (peri-menopausal women with pre-existing MASLD) (HR 0.90, 95% CI 0.84-0.96).
“reduced risk of cardiometabolic outcomes: T2D (0.90; 0.84, 0.96)”
Humansperi-menopausal women with pre-existing MASLD5 yearsfemales
Studies name bilateral salpingo-oophorectomy as acting on hormone replacement therapy.
Bilateral salpingo-oophorectomy
↑upin humans1
1 study
Bilateral salpingo-oophorectomy is linked with higher hormone replacement therapy in humans during benign hysterectomy in postmenopausal individuals (aHR 2.04 (95% CI 1.92-2.17)).
“The likelihood of starting menopausal hormone therapy after surgery was significantly higher for those who had hysterectomy with bilateral oophorectomy compared to hysterectomy with ovarian conservation (adjusted hazard ratio, 2.04; 95% confidence interval, 1.92-2.17).”
Humansduring benign hysterectomy in postmenopausal individualsfemalesn = 18,676
Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).Compared with under 30 years, at least 40 years between first period and menopause was linked to lower osteoporosis risk (hazard ratio 0.82).